Drug intelligence / Profile preview

WJ06

Development stage: Unknown
Lead developer: Wigen Biomedicine Technology
Modality: Small Molecules
Administration: Oral

Overview

WJ06 is a small molecule inhibitor of Focal Adhesion Kinase (FAK) currently under development by Wigen Biomedicine Technology (Shanghai). FAK is a non-receptor tyrosine kinase that is frequently overexpressed in a variety of solid tumors, where it mediates signaling pathways involved in cell adhesion, motility, proliferation, and survival. By targeting FAK, WJ06 is designed to inhibit tumor progression and metastasis. The compound is being investigated for its potential application in oncology, though specific indications and clinical trial phases have not been widely disclosed.

Targets

FAK (Focal adhesion kinase)

Beyond the preview

Go deeper on WJ06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WJ06.

Explore the full profile